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Retrospective analysis of the efficacy 
and safety of cabazitaxel treatment  
in castration-resistant prostate cancer 
after docetaxel failure
ABSTRACT 
Introduction. Cabazitaxel has been approved by the FDA and EMEA for the treatment of metastatic castra-
tion-resistant prostate cancer (mCRPC) after failure of docetaxel-based chemotherapy. Between June 2011 and 
November 2013 cabazitaxel was reimbursed for Polish mCRPC patients as a non-standard chemotherapy. The 
study objective was a retrospective analysis of the efficacy and safety data of mCRPC patients treated with 
cabazitaxel in this period. 
Material and methods. Collection of retrospective data on 48 consecutive mCRPC patients treated with cabazitaxel 
after docetaxel failure. Data on baseline characteristics, cancer history, and the efficacy and safety of cabazitaxel 
treatment were collected. Progression-free survival (PFS) (radiological/clinical/biochemical) and overall survival 
(OS) were estimated by the Kaplan-Meier method. Objective response rate and clinical benefit were also assessed. 
Results. Forty-eight patients were included. Median PFS was 4.2 (95% CI 3.4–5.1) months, and median OS was 
15.1 (95% CI 12.7–17.4) months. OS since docetaxel initiation in patients treated with cabazitaxel as second-line 
chemotherapy (n = 47) was 28.7 (95% CI 25,3–32,1) months. OS rates at 1, 2, and 3 years after first cabazitaxel 
cycle were 65%, 25%, and 15%, respectively. In total, 289 cycles of cabazitaxel were administered (mean six per 
patient). There were 41 patients evaluable for biochemical response, 19/41 (46%) of whom had a PSA decrease of 
at least 50% from baseline, including 3/41 who had an initial PSA flare followed by a decrease of at least 50% from 
baseline. Adverse events comprised predominantly haematological (26 patients) and gastrointestinal (14 patients) 
toxicities. Ten SAEs were reported, including one death due to acute renal failure. 
Conclusions. Treatment of mCRPC patients with cabazitaxel after docetaxel failure is an important therapeutic 
option with acceptable toxicity with respect to clinical stabilisation and possibly increased survival. 
Key words: castration-resistant prostate cancer, cabazitaxel, prostate-specific antigen, chemotherapy, cytotoxic 
agent, progression-free survival, overall survival, time to treatment failure
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Introduction 
Prostate cancer is the most commonly diagnosed 
cancer in men; it is the third most common cause of 
cancer deaths in men after lung cancer and colorectal 
cancer in Europe [1].
Treatment of advanced/metastatic prostate cancer 
is palliative, and the main form of systemic therapy is 
endocrine therapy based on androgen ablation (surgical 
or pharmacological castration). Endocrine treatment in 
advanced symptomatic prostate cancer patients allows 
achievement of rapid clinical response (decrease in the 
severity of bone pain, tumour burden reduction), and a bio-
chemical response (decreased level of prostate-specific 
antigen (PSA). However, at some point in time (median 
18–24 months), cancer becomes resistant to castration in all 
patients (castration-resistant prostate cancer, CRPC) [2].
Unti l  2010 chemotherapy with docetaxel 
(75 mg/m2 every 21 days IV) in combination with pred-
nisone was the only therapy significantly improving 
overall survival (OS) in metastatic CRPC (mCRPC) 
patients. Two prospective randomised phase III stud-
ies (TAX327 and SWOG 9916), which enrolled ap-
proximately 2000 men [3–5], demonstrated a significant 
superiority of docetaxel compared to mitoxantrone 
in mCRPC patients. Docetaxel in combination with 
prednisone given every 21 days reduced the relative 
risk of death by 24% compared with the combination 
of mitoxantrone plus prednisone (HR 0.76 [95% CI, 
0.62–0.92]), while reducing the severity of pain and 
positively affecting the patients’ quality of life.
Cabazitaxel is a novel generation taxane, which was 
designed de novo to overcome resistance to docetaxel. 
It has been shown that cabazitaxel is comparable to 
docetaxel in terms of efficacy in tumour cells sensitive 
to docetaxel, but in docetaxel-resistant cell lines and 
tumours it demonstrates 10-times higher anticancer 
activity [6]. It was further shown that cabazitaxel, con-
trary to paclitaxel and docetaxel, crosses the blood-brain 
barrier in vivo, and therefore may exhibit anticancer 
activity in patients with brain or lepto-meningeal 
metastases. The efficacy of cabazitaxel in the treat-
ment of mCRPC was demonstrated in a phase III 
study, TROPIC, which enrolled 755 men who had 
progressed during or after treatment with docetaxel. 
Patients were randomly assigned in a 1:1 ratio to the 
experimental arm (cabazitaxel 25 mg/m2 IV every three 
weeks + prednisone 10 mg/day) or the control arm 
(mitoxantrone 12 mg/m2 IV every three weeks + pred-
nisone 10 mg/day). In both arms, up to 10 courses of 
chemotherapy could be administered [7]. The study 
met its primary endpoint, achieving a significant im-
provement in overall survival in patients treated with 
cabazitaxel compared to mitoxantrone (15.1 months 
vs. 12.7 months, respectively), which translated into 
a significant reduction in the relative risk of death 
by 30% (HR 0.70; 95% CI, 0.59–0.83). Median pro-
gression-free survival (PFS), which was a composite 
endpoint defined as time from randomisation to dis-
ease progression (biochemical, radiological, or clinical 
progression) or death, was 2.8 months in the cabazitaxel 
group vs. 1.4 months in the mitoxantrone group (HR 
0.74; 95% CI, 0.64–0.86). Biochemical and radiological 
responses were also significantly more frequent with 
cabazitaxel compared to mitoxantrone. The updated 
TROPIC study data confirmed continuous improve-
ment of OS: the two-year survival rate was 15.9% in 
the cabazitaxel arm and 8.2% in the mitoxantrone arm 
[8]. Based on the TROPIC study, cabazitaxel has been 
approved by the FDA and EMEA for the treatment 
of mCRPC patients after failure of docetaxel-based 
chemotherapy. It was subsequently shown in a phase 
II prospective, randomised trial that cabazitaxel retains 
its activity in patients who have progressed on novel 
androgen receptor-targeting agents [9].
In the period from June 2011 to November 
2013 cabazitaxel was reimbursed for Polish mCRPC 
patients as a non-standard chemotherapy. The aim of 
this multicentre, retrospective, observational study was 
to analyse data on the efficacy and safety of treatment 
with cabazitaxel in the population of Polish patients with 
mCRPC after docetaxel failure. 
Material and methods 
Data on the efficacy and safety of cabazitaxel was 
collected for patients who received at least one course 
of chemotherapy (with cabazitaxel followed docetaxel) as 
part of a non-standard chemotherapy reimbursement pro-
cedure in the period from 1 June 2011 to 31 August 2013. 
Statistical analyses were descriptive [10, 11]. The pri-
mary end-point was progression-free survival (defined 
as time to PSA and/or radiological progression and/or 
clinical progression and/or death). Secondary end-points 
included PSA response rate (defined by a PSA decrease 
of at least 50% from baseline after three cycles), num-
ber of patients with PSA flare during the first 12 weeks 
of therapy, clinical benefit as per physician judgment 
(based on performance status, pain, and analgesic con-
sumption), OS, safety (incidence of adverse events and 
serious adverse events), and usage of G-CSF.
Sample size
It was planned to collect data on approximately 
50 patients. This number was based on the estimated 
number of patients treated with cabazitaxel in the pe-
riod 2011–2013 within the framework of non-standard 
chemotherapy reimbursement procedure in Poland. 
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The study was approved by the Ethics Committee at 
the Cancer Centre — Maria Skłodowska-Curie Memo-
rial in Warsaw.
Data collected 
The data were collected on the basis of a review 
of medical source records of mCRPC patients treated 
with cabazitaxel. The information covering at least 
12 months from the start of cabazitaxel treatment was 
analysed for each patient included in the study. The 
study design reflected the management of these patients 
in a real-life setting. Collected retrospective data were 
related to the primary histopathological data on pros-
tate cancer, information about prior curative treatment 
and palliative care (surgery, radiotherapy, hormone 
therapy, chemotherapy), changes in the PSA levels in 
the course of the disease, and the use of cabazitaxel in 
patients with castration-refractory prostate cancer — see 
details below.
The following data were collected at initiation of 
cabazitaxel therapy: age, the presence of metastases, 
their location (bone, lymph nodes, visceral), and dis-
ease burden (massive spread, defined as the presence 
of visceral metastases and/or ≥ 4 bone metastases, 
including at least one outside the pelvis and the spine); 
progression type (biochemical/clinical/radiological); 
the presence of measurable disease (according to the 
standard criteria used at a given site or as defined by 
RECIST); the presence of symptoms; performance 
status (according to ECOG); changes in PSA value; 
and other laboratory parameters. In the case of pain, 
information on the analgesics used was additionally col-
lected (trade name of the drug, number of applications 
per day, and/or daily dose).
Moreover, for the period of cabazitaxel treatment, 
the following data were also collected: all adverse events 
(AEs) and serious adverse events (SAEs), grade 3–4 ad-
verse events by WHO regarding hormone therapy and 
chemotherapy with cabazitaxel during follow-up; date 
of last visit during follow-up; disease progression: yes 
or no; type and date of progression; date of the last 
dose of the drug; and the patient’s condition during the 
last visit in the follow-up period: survival, death (date), 
cause of death.
Results
From the seven Polish cancer centres participating in 
the study, 48 patients with metastatic castration-resistant 
prostate cancer treated with cabazitaxel after failure of 
docetaxel treatment were identified. 
Disease history of patients enrolled in the registry 
is provided in Table 1. The majority of patients were 
Table 1. Disease history of patients included in the study
Number  
of patients  
(n = 48) 
Histopathological diagnosis 
      Adenocarcinoma 45
      N/A 3
Histological grade in the Gleason scale (2–10)
      < 7 13
      7 11
      8 11
      9 9
      N/A 4
Clinical stage at diagnosis
      T2, M0 9
      T3–T4, M0 6
      M1 16
      N/A 17
Prior treatment with curative intent
      Radical prostatectomy 9
      External beam radiation therapy 20
      Brachytherapy 1
diagnosed with primarily metastatic disease with a high 
Gleason score (≥ 8). 
In most cases, first-line endocrine therapy was phar-
macological castration — only one patient underwent 
orchiectomy (2%). Half of the evaluated patients under-
went secondary hormonal manipulations as part (mainly 
with the use of maximum androgen blockade (flutamide, 
bicalutamide); seven men (15% of the group) were 
treated with abiraterone acetate. In 47 of 48 patients 
first-line chemotherapy was based on docetaxel; one pa-
tient received mitoxantrone as first-line chemotherapy. 
Less than half of the analysed patients (17 of 48; 35%) 
received second-line chemotherapy (mostly docetaxel 
or mitoxantrone) before cabazitaxel initiation. 
Treatment with cabazitaxel was preceded by a re-as-
sessment of disease severity, the number and location 
of metastases, performance status, disease progression 
diagnosis method, PSA levels, and the use of analge-
sics. Cabazitaxel initiation was associated with clinical 
progression in 35% and radiological progression in 29%. 
A significant percentage of patients (25 out of 48-men) 
met the criteria for diagnosis of massively advanced 
metastatic disease (the category “Many metastases”). 
ECOG performance status score was mainly 2 or higher 
(n = 30). Detailed data are provided in Table 2. In to-
tal, the study group reported 289 cycles of cabazitaxel 
treatment (an average of six cycles of chemotherapy per 
patient), and 16 out of 48 men (33%) included in the 
analysis received the planned number of chemotherapy 
cycles. In 230 cycles (80%) the typical dose of cabazi-
taxel (25 mg/m2) was used, in 40 cycles (14%) the dose 
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Table 2. Patient characteristics at initiation of cabazitaxel 
therapy
n = 48 
Age, years — median (range) 65 (45–80)
Metastases — location
     Bones 41
     Lymph nodes 15
     Visceral organs 7
     Numerous metastases 25
     Missing data 4
Progression
     Biochemical 44
     Clinical 17
     Radiological 14
     — in scintigraphy 12
Opioid analgesics daily 9
Non-opioid analgesics daily 6
ECOG 
     0–1 14
     2 24
     > 2 6
     N/A 5
PSA [ng/ml] (mean, median) 326; 186
Table 3. Course of cabazitaxel therapy
 Number of 
patients/number 
of cycles
Number of cycles administered 289
     Mean (± SD); range 6.0 (3.4); 1–18
     Median 5.0
     1–6 31
     7–10 14
     > 10 3
Number of patients who received the 
planned number of cycles (4–13 cycles)
25
N patients (%) with dose reduction 8/48 (16.7%)
N cycles/total number of cycles with 
a reduced dose
19/289 (7%)
N cycles delayed/total number of cycles (%) 46/289 (16%)
     Due to toxicity 20 (7%)
     For other reasons (usually 
     unavailability of the drug)
26 (9%)
Prednisone (number of cycles) 253/289 (88%)
Table 4. Reasons for termination of cabazitaxel chemo-
therapy1 
Number of 
patients (n = 48)
Treatment completion, planned number 
of chemotherapy courses
16
Biochemical progression 17
Clinical progression 6
Radiological progression 1
Worsening of performance status 10
Toxicity (WHO grade 3–4 adverse events) 5
Other (e.g. death) 3 (2)
1There could be more than one cause in a single patient
was reduced to 20 mg/m2, and there was even a greater 
reduction of cabazitaxel dose in a total of 19 cycles. The 
dose reduction in eight patients was associated with 
adverse events (a total of 19 cycles of chemotherapy, 
representing 7% of the administered courses). Chemo-
therapy was delayed in 46 cycles of treatment, of which 
only 20 (7% of all) were delayed due to toxicity. Delays 
for any other reason, including unavailability of the 
drug, occurred in 26/289 (9%) cycles. Prednisone was 
administered in 253/289 (88%) cycles. Table 3 shows 
the parameters related to cabazitaxel dosage. The 
most commonly used concomitant medications were 
bisphosphonates (34/48) and denosumab (2/48) — 85% 
of patients had bone metastases. The G-CSF support 
was used in 19/48 patients. Opioid analgesics were ad-
ministered daily in 9/48 (19%), and non-opioid drugs in 
6/48 (13%) of patients.
The reasons for discontinuing cabazitaxel therapy are 
presented in Table 4. In most cases, chemotherapy was 
discontinued after administration of a pre-planned num-
ber of cycles, or due to biochemical progression — 33% 
and 35% of cases, respectively. The next most common 
cause of treatment cessation was performance status 
deterioration (21%). In two cases, the treatment was 
not completed due to the patient’s death. Finally, cancer 
progression was seen in 41 of 48 (85%) men included in 
the analysis. The most common forms of progression were 
biochemical progression (increase in PSA levels above the 
defined value) — 17/48 (35%) and clinical progression 
(worsening of performance status and an increase in pain 
severity) — 6/48 (13%). Serious skeletal-related events 
(SRE) were reported in seven patients (15%).
PSA response was evaluable in 41 patients as per 
prostate cancer working group recommendations (i.e. 
at least three cycles of cabazitaxel). Of these 41 patients, 
19 (46%) had a PSA decrease of at least 50%, including 
three who had an initial PSA flare followed by PSA drop 
below 50% of baseline. Median PFS was 4.2 months 
(95% CI: 3.4–5.1), and median OS was 12.8 months 
(95% CI: 9.7–15.9). Detailed data on the primary end-
point (progression-free survival) and OS are presented 
in Table 5. One-year survival rate in the study group was 
65%, and two-year and three-year survival rates were 
25% and 15%, respectively. A graphical representation 
of PFS and OS analysis using the Kaplan-Meier method 
is presented in Figure 1 and 2. 
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Table 5. Cabazitaxel therapy efficacy assessment — progression-free survival (since cabazitaxel initiation until progression 
for whatever reason) and overall survival  
Progression-free survival (PFS) and overall survival (OS) in months for cabazitaxel-treated patients
PFS Number of patients Median 95% Cl
Confirmed 44 4.2 3.4–5.1
Generalised1 48 4.1 3.3–5.1
OS Number of patients Median 95% Cl
With known date 14 12.8 9.7–15.9
Confirmed2 19 10.5 7.9–13.1
Generalised1 48 15.1 12.7–17.4
1In both generalisations — the date of the last contact with the patient was used
2In case of the lack of the death date — the date of the last contact with the patient was used
Figure 1. Kaplan-Meier analysis of progression-free survival (PFS) in cabazitaxel-treated patients
Figure 2. Kaplan-Meier analysis of overall survival in patients treated with cabazitaxel (n = 48)
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Kaplan-Meier progression-free survival for 48 patients treated with cabazitaxel
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Figure 3. Kaplan-Meier analysis of overall survival since docetaxel initiation in patients treated with cabazitaxel as second-line 
chemotherapy (n = 47)
Figure 4. Percentage changes in PSA levels from baseline in the consecutive cycles of cabazitaxel therapy
The overall survival estimate since docetaxel 
initiation is presented in Figure 3. The OS median was 
28.70 (95% CI: 25.30–32.10) months.
In order to reliably assess OS in cabazitaxel-treated 
patients, data on next-line systemic therapy was collected 
(after the end of cabazitaxel therapy). Forty-seven pa-
tients (the date of docetaxel initiation in one patient was 
unavailable) were administered a treatment sequence of 
docetaxel-cabazitaxel after failure of endocrine therapy. 
Nine patients (19%) in this study population received 
abiraterone acetate after progression on cabazitaxel. 
One of them received cabazitaxel rechallenge (six cycles 
until biochemical progression; previously 10 cycles) after 
discontinuation of abiraterone. No data on response to 
abiraterone was collected.
Serum PSA level variations observed during cabazi-
taxel treatment, their range, and dynamics are presented 
in Figure 4.
Clinical benefit from cabazitaxel, defined as objective 
responses or disease stabilisation, was verified after each 
cycle of chemotherapy (Table 6). Furthermore, clinical 
response (improvement in performance status and/or de-
crease in the severity of pain and/or reduction of the need 
for analgesics) was seen after administration of 53 out of 
289 cycles of cabazitaxel treatment. Four of nine patients 
administered with narcotic analgesics and 4/6 patients 
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Table 6. Clinical effects of cabazitaxel therapy 
Number  
of cycles  
(n = 289) 
Clinical benefit during cabazitaxel therapy 
— evaluation after each cycle
      Improvement in ECOG performance status1 21
      Pain severity reduction 24
      Reduction of the need for analgesics2 53
      Stable condition 174 (60%)
      No response 22 (7%)
      N/A 59 (20%)
1ECOG performance status improved in 4 patients with ECOG 3, in 5 patients 
with ECOG 2, and in 1 patient with ECOG 1 prior to cabazitaxel
24/9 and 4/6 patients, respectively, had their need for narcotic and non-nar-
cotic daily analgesics at cabazitaxel initiation reduced
taking non-narcotic analgesics at initiation of cabazitaxel 
therapy responded with reduction of the need for analgesics. 
In the analysis of investigator-reported adverse events 
(AE) associated with cabazitaxel, there was a prevalence 
of haematological complications with anaemia (10 cases 
[20.8%], including three cases [6.3%] in grade 3 of severity 
according to the WHO), neutropaenia (nine cases, repre-
senting 18.8% of the group, including two cases [4.2%] in 
grade 3, and two cases in grade 4), and thrombocytopaenia 
(10.4%), mainly in grade 1 and 2. Gastrointestinal adverse 
events (nine cases of diarrhoea [18.8%], and two cases 
[4.2%] each of vomiting and abdominal pain) were the 
second most common AEs; however, their severity did not 
exceed WHO grade 2. Symptoms of polyneuropathy (only 
sensory) was observed only in two patients (4.2%), and 
their severity did not exceed grade 2. The following cor-
rective actions were taken: extending the interval between 
cycles (14 patients, 29 cycles), dose reduction (8 patients, 
19 cycles), discontinuation of treatment (8 patients). 
Detailed data on adverse events are presented in Table 7.
Ten serious adverse events (SAEs) related to 
cabazitaxel were reported, including one fatal event 
due to acute renal failure eight months from the start 
of cabazitaxel therapy (nine cycles). The others were: 
anaemia (three times in the same patient), febrile neu-
tropaenia (1), febrile neutropaenia with diarrhoea and 
haematuria (1), secondary neutropaenia (1), diarrhoea 
with abdominal pain and vomiting (1), myocardial in-
farction (1), unstable coronary disease (1).
Discussion
Data from seven national cancer centres, derived 
from 48 patients with mCRPC receiving cabazitaxel, 
allowed a retrospective evaluation of the efficacy and 
safety of this drug in routine clinical practice. 
Table 7. Safety assessment of cabazitaxel therapy — adverse 
events reported
Adverse event Number  
of cases  
(n = 50)*
3˚  
(n = 12) 
4˚  
(n = 5)
Haematological 
     Anaemia 10 3 –
     Neutropenia 8 2 2
     Thrombocytopenia 4 1 –
     Leucopaenia 2 1 1
     Febrile neutropaenia 2 1 –
Gastrointestinal tract
     Diarrhoea 10 – –
     Vomiting 2 – –
     Abdominal pain 2 – –
     Enteritis 1 1 –
Urinary tract system
     Acute renal failure 1 – 1
     Urinary incontinence 1 1 –
     Urinary tract infection 1 – –
Cardiovascular system
     Myocardial infarction 1 – 1
     Unstable coronary 
      artery disease
1 1 –
Other
     Paresthesia 2 1 –
     Dehydration 1 – –
     Secondary neutropaenia 1 – –
*44 adverse events occurred during cabazitaxel therapy
On the basis of the performed analyses, it was 
shown that in the vast majority of patients, cabazitaxel 
was used in accordance with the Summary of Product 
Characteristics (in combination with prednisone), and 
more than half of the patients received treatment with 
the planned intensity. Dose reductions or delays in the 
administration of the planned courses of chemotherapy 
were caused by both toxicity and problems with drug 
availability. The vast majority of patients did not re-
ceive primary prevention of febrile neutropaenia. In 
the period covered by the retrospective analysis, the 
majority of patients experienced disease progression. 
Median overall survival and progression-free survival in 
the analysed population were characterised by similar 
values as in the pivotal study [12].
The use of cabazitaxel was associated with the oc-
currence of adverse events of all grades; however, their 
frequency was comparable to the pivotal study, and the 
incidence of serious adverse events was relatively low 
compared to the pivotal study. 
Cabazitaxel, in addition to docetaxel, is one of two 
cytotoxic drugs that significantly improve the prognosis in 
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patients with castration-resistant prostate cancer. This drug, 
in addition to two hormonal drugs (abiraterone acetate and 
enzalutamide), is a systemic treatment option for patients 
with mCRPC after failure of docetaxel therapy. It is an espe-
cially active drug in patients who have progressed during or 
after docetaxel [12, 13], and it retains its activity in patients 
progressing after novel AR-targeted agents [9]. Unlike 
cabazitaxel, both abiraterone acetate and enzalutamide can 
be used, in accordance with their approved indications, in 
mCRPC patients who still do not require docetaxel. Thus, 
the value of cabazitaxel, as a drug with proven therapeutic 
effect in patients after failure of docetaxel-based chemo-
therapy, who have already failed new-generation endocrine 
therapy. Is estimaeted important data were recently pre-
sented at the Congress of the American Society of Clinical 
Oncology — ASCO 2016. A phase III study comparing 
two doses of cabazitaxel (25 mg/m2 and 20 mg/m2) in the 
treatment of mCRPC patients after failure of docetaxel 
therapy demonstrated comparable efficacy of the two doses, 
with a clear reduction of toxicity in patients receiving the 
lower dose. Also, taking into account the beneficial effect 
of cabazitaxel on the quality of life of mCRPC patients, 
which was shown, among others, in an expanded access 
study conducted in the UK [14], this drug can certainly be 
considered a valuable therapeutic option in clinical prac-
tice. A randomised trial of cabazitaxel was also recently 
presented at the European Society of Medical Oncology 
(ESMO) Annual Meeting showed a significantly greater ac-
tivity than abiraterone or enzalutamide in mCRPC patients 
with high-risk features (liver metastases, time to castration 
less than one year with first androgen deprivation therapy, 
high LDH — Kim Chi ESMO 2018) [15].
Conclusions
In this cohort of patients cabazitaxel showed it can 
be an good therapeutic option for patients with meta-
static castration-resistant prostate cancer after docetaxel 
failure and is an important therapeutic option with 
acceptable toxicity with respect to clinical stabilisation 
and possibly increased survival. 
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